Johnson & Johnson Private Limited
Clinical trials sponsored by Johnson & Johnson Private Limited, explained in plain language.
Now part of
Johnson & Johnson
JNJ
NYSE
Indian subsidiary of the global healthcare giant Johnson & Johnson.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug teclistamab tested for safety in Tough-to-Treat blood cancer Results expected Nov 2026 (estimated)
- New hope for indian patients with psoriatic arthritis: guselkumab trial launches Results expected Jun 2027 (estimated)